Return to
www.tearscience.com
- Home
- Market[h5]The Real Cause and Extent of Evaporative Dry Eye[/h5] Sixty-five percent (65%) of patients with symptoms of Dry Eye have meibomian gland dysfunctions or MGD1. This large pool of patients, currently suffering pain and discomfort, may benefit from an entirely new approach to treatment. Responding to an unmet need The very real suffering of patients, who present with dry eye symptoms, has been a continual frustration for physicians and patients for years. With limited tools to treat the cause, often patients experienced mild, short-term, and inconsistent relief. As research has uncovered the origins of evaporative dry eye, traditional treatment approaches have limitations in efficacy2. By incorporating this new information into treatment protocols, ophthalmic professionals have the opportunity to improve clinical outcomes and patient satisfaction in their practices. [frame style="modern" image_path="http://www.tearflow.com/wp-content/uploads/2011/06/pie-chart.jpg" link_to_page="" target="" description="" size="two_col_large"] The types of Dry Eye There are two predominant forms of Dry Eye. Evaporative, due to lipid deficiency, is the most prevalent, affecting 65% of sufferers. Evaporative Dry Eye (65% of patients with dry eye symptoms) Occurs when the aqueous evaporates at a faster rate than normal due to an inadequate protective lipid (oil) layer on the surface of the tear film. This is a manifestation…
- Technology[h5]Effective treatment for Evaporative Dry Eye[/h5] With the introduction of the LipiFlow® for treatment, TearScience® makes it possible to effectively treat the root cause of evaporative dry eye. More than 20 years of clinical research and anatomical findings have led to this breakthrough technology. LipiView® Ocular Surface Interferometer enables the physician to capture digital images of patients’ tear film. LipiFlow® Thermal Pulsation System has been clinically demonstrated to significantly improve the secretions of the meibomian glands and reduce dry eye symptoms, on average. [one_half] [frame style="modern" image_path="http://www.tearflow.com/wp-content/uploads/2011/06/LipiView-black-screen1.jpg" link_to_page="" target="" description="" size="two_col_large"] LipiView® Ocular Surface Interferometer [/one_half] [one_half_last] [frame style="modern" image_path="http://www.tearflow.com/wp-content/uploads/2011/06/LipiFlow-Auto1.jpg" link_to_page="" target="" description="" size="two_col_large"] LipiFlow® Thermal Pulsation System [/one_half_last]
- Procedure[h5]A breakthrough innovation in the treatment of Evaporative Dry Eye[/h5] Over the last 10 years, every ocular condition has experienced a game-changing procedural innovation – except one. With the introduction of the breakthrough LipiFlow®, Dry Eye has now leapt to the forefront of technological advances. Leaving behind a frustrating history of time-consuming, imprecise tests, with no clear differential, and modestly effective treatments. The number of diagnostic tests available for the evaluation of tear film disorders and ocular surface compromise can create confusion. A recent survey of physicians reveals that they attempt multiple types of treatments to treat moderate to severe dry eye.6 Moving forward with advanced, proven science Tear film observation…effective, in-office treatment…a single, breakthrough system Introduced into this world of confusing, imprecise diagnostics and mostly palliative therapies, TearScience® technology represents a major shift in the science of dry eye. Once Meibomian Gland Dysfunction and Evaporative Dry Eye are identified, the LipiFlow® Thermal Pulsation System is designed to relieve both symptoms and cause, by clearing blocked meibomian glands. Satisfied dry eye patients in the practice Now, with the introduction of the TearScience® System, an office-based treatment system is available with an in-office procedure, enhancing the health…
- Science[h5]Citations[/h5] 1Shimazaki J, Sakata M, Tsuboto K. Ocular Surface Changes and Discomfort in Patients With Meibomian Gland Dysfunction. Arch Ophthalmol. 1995;113(10):1266-1270. 2Blackie C, Korb D, Knop E, Bedi R, Knop N, Holland E. Nonobvious Obstructive Meibomian Gland Dysfunction. Cornea. 2010 Dec; (12): 1333-1345. 3Patient and Physician focus groups. Data on file. 4 The International Workshop on Meibomian Gland Dysfunction: Executive Summary, doi: 10.1167/iovs.10-6997a Invest. Ophthalmol. Vis. Sci. March 30, 2011 vol. 52 no. 4 1922-1929 5Clinical Study LF001. Data on file. 6 Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009 Apr; Supplement 7(2 Suppl):S1-S14.
- EventsTrade Shows Visit TearScience at these industry events to learn more about our breakthrough LipiFlow treatment for evaporative dry eye: Show Exhibit Dates Location LipiFlow workshop at Royal Hawaii Eye January 18, 2012 Four Seasons Hotel, Maui, Hawaii Augenärztlichen Akademie Deutschland Mar. 20-29, 2012 Dusseldorf, Germany ASCRS Apr. 20-24, 2012 Chicago, Illinois BVA May 9-10, 2012 Weisbaden, Germany Canadian Ophthalmological Society June 26-30, 2012 Toronto, Canada ESCRS Sep. 8-12, 2012 Milan, Italy AAO Nov. 10-13, 2012 Chicago, Illinois
-
-
LipiView Interferometer
A new, in-office device for observing the tear film. LipiView captures detailed images of the tear film in less than 5 minutes.
Find out more here
-
LipiFlow Thermal Pulsation
A breakthrough device for treating evaporative dry eye patients with a 12-minute, in-office procedure. LipiFlow applies heat to the back of the eyelid and intermittent, gentle pressure to the outside surface to release the obstruction from meibomian glands and allow the natural flow of lipids to resume.
Watch the LipiFlow video here
-
-
-
Clinical Results
The average meibomian gland score for patients who received a single LipiFlow treatment more than doubled. The increase in the average total meibomian gland score indicates an increase in the number of glands secreting and a higher quality of gland secretions as compared to before LipiFlow treatment.
Click here to find out more.
-
Symptom Relief
The mean Ocular Surface Disease Index (OSDI) improved from 32.0 ± 20.0 at baseline to 16.6 ± 18.1 at 4 weeks, demonstrating reduction in dry eye symptoms.
To read more about patient benefits click here.
